8 September 2026
Aspen Pharmacare earnings rose 22% as demand for Eli Lilly's weight-loss drug Mounjaro surged, with the group also eyeing generic semaglutide.
16 July 2026
Sun Pharma’s Generic Semaglutide is now available in South Africa. Explore this new treatment option for type 2 diabetes.
25 June 2026
US prescription drug spending is forecast to exceed $560bn in 2026 as demand for GLP-1 obesity and diabetes treatments continues to rise.
9 February 2026
14 January 2026
Aspen APAC divestment unlocks R26.5bn in capital, sharpening the group’s focus on GLP-1 injectables and reducing net debt heading into 2026.
24 November 2025
Eli Lilly hits $1 trillion valuation, marking a historic milestone in the pharmaceutical industry with successful weight-loss drugs.
5 November 2025
Aspen's Mounjaro expansion plans promise to enhance diabetes and weight management treatment in Sub-Saharan Africa soon.
15 October 2025
Aspen shares soar following the approval of Mounjaro for weight loss in South Africa. Discover the impact on obesity management.
22 August 2025
Novo Nordisk implements a hiring freeze as layoffs approach after Wegovy's success. Discover the impact on the pharmaceutical industry.
29 June 2025
Understand the significance of Ozempic and Mounjaro in the evolving landscape of diabetes care and weight management in South Africa.
29 June 2025
Orforglipron can offer a new oral option for managing weight loss and blood sugar in type 2 diabetes treatment.
8 November 2024
ObesityWeek 2024 attracted unprecedented attention from Wall Street, highlighting obesity treatment's booming pharmaceutical industry.